References for this Review were identified through searches of PubMed with the search terms “Parkinson's disease”, “inflammation”, “cytokine”, glial cell”, “microglia”, “astrocyte”, “lymphocyte”, “MPTP”, and “6-hydroxydopamine” between January, 1988, and January, 2009. Further papers were identified from the references cited in those articles. Only papers published in English were reviewed. The final reference list was generated from papers that were relevant to the topics covered in this
ReviewNeuroinflammation in Parkinson's disease: a target for neuroprotection?
Introduction
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease. It is characterised by a slow and progressive degeneration of dopaminergic neurons in the substantia nigra. Yet, other dopaminergic neurons are also affected, although to a lesser extent.1 This loss of dopaminergic neurons causes most of the motor symptoms of Parkinson's disease, which can be alleviated by restoring neurotransmission with the dopamine precursor levodopa or with dopaminergic agonists. Nevertheless, patients with Parkinson's disease also have levodopa-resistant symptoms, suggesting that non-dopaminergic systems are affected as well.2 For example, non-dopaminergic neurons, including norepinephrinergic neurons in the locus coeruleus, cholinergic neurons in the basal forebrain and the brainstem, and serotoninergic neurons in the raphe nuclei, are also affected by the pathological process. Even neurons outside the CNS, such as those in the olfactory bulb or mesenteric system, degenerate in Parkinson's disease. In addition to the neuronal loss, this disorder is pathologically characterised by the presence of proteinaceous inclusions, such as Lewy bodies or Lewy neurites. These inclusions seem to emerge following an ascending gradient that originates within the lower brainstem, expands to the basal ganglia, and ends in the cerebral cortex.3
Despite intensive research, the cause of neuronal loss in Parkinson's disease and the role of these protein inclusions are not fully understood. However, several molecular and cellular changes that might be involved in neuronal degeneration have been identified, including abnormal protein handling, oxidative stress, mitochondrial dysfunction, excitotoxicity, and apoptotic processes. Neuroinflammatory mechanisms probably also contribute to the cascade of events leading to neuronal degeneration. These mechanisms comprise microglial activation, astrogliosis, and lymphocytic infiltration (figure 1). However, it must be emphasised that these changes are unlikely to be specific for Parkinson's disease, because neuroinflammatory processes contribute to several neurodegenerative disorders, such as Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, and progressive supranuclear palsy.4 This does not imply that neuroinflammation is merely a consequence of neuronal degeneration, as several lines of evidence suggest that it might be involved in the progression of neuronal degeneration by producing deleterious proinflammatory molecules. In this Review, we describe the evidence for neuroinflammatory processes in Parkinson's disease, and the cellular and molecular events associated with neuroinflammation involved in the degeneration of dopaminergic neurons in animal models. Finally, we highlight possible therapeutic targets associated with inflammation that might help to slow down the progression of this neurodegenerative disease.
Section snippets
Post-mortem studies
Data from post-mortem studies provided the first evidence for neuroinflammatory processes in Parkinson's disease. In 1988, McGeer and co-workers5 reported the presence of activated microglial cells within the substantia nigra of patients with Parkinson's disease at post-mortem. These cells were identified by their immunoreactivity to human leucocyte antigen DR (HLA-DR), a cell-surface receptor belonging to the MHC class II. This seminal finding was confirmed by other investigators using
Animal models
Both the cellular and molecular changes seen in the brains of patients with Parkinson's disease have been reproduced in several animal models. The blockade of these changes in animals has provided strong evidence to suggest that neuroinflammatory processes are involved in the death of dopaminergic neurons. In this section we discuss the cellular changes and describe the molecular pathways involved in the neuroinflammatory processes in various animal models of Parkinson's disease.
Therapeutic developments and future directions
The extensive, and still growing, body of evidence discussed above indicates that neuroinflammatory processes are probably involved in the pathophysiology of Parkinson's disease. However, the origin and role of these neuroinflammatory changes need to be established. Neuroinflammation might be a simple consequence of neuronal changes or degeneration. Alternatively, neuroinflammatory processes might be a main cause of the disease. The role of an autoimmune reaction in Parkinson's disease is
Conclusions
Since microglial cell activation was first characterised in the brains of patients with parkinsonian symptoms 20 years ago,5 there has been great interest and developments in the study of neuroinflammation in Parkinson's disease. As can be seen from the data reviewed here, neuroinflammation is now recognised as an important pathophysiological feature of this neurodegenerative disorder. However, despite the progress made so far, one question remains: are immune-associated mechanisms the main
Search strategy and selection criteria
References (179)
- et al.
Glutathione peroxidase, glial cells and Parkinson's disease
Neuroscience
(1993) - et al.
Blood vessels change in the mesencephalon of patients with Parkinson's disease
Lancet
(1999) - et al.
Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients
Neurosci Lett
(1994) - et al.
Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients
Neurosci Lett
(1994) - et al.
Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease
Neurosci Lett
(1995) - et al.
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease
Neurosci Lett
(1994) - et al.
Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death
Brain Res
(1992) - et al.
Nitric oxide synthase and neuronal vulnerability in Parkinson's disease
Neuroscience
(1996) - et al.
Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2
Mol Cell Neurosci
(2000) - et al.
p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain
Neurosci Lett
(2007)
Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism
J Neuroimmunol
Correlation study between serum adenosine deaminase activities and peripheral lymphocyte subsets in Parkinson's disease
J Neurol Sci
Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration
J Neuroimmunol
Alterations of T-lymphocyte populations in Parkinson disease
Parkinsonism Relat Disord
Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model
Neurobiol Dis
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Neurobiol Dis
Association of interleukin-1 beta polymorphisms with idiopathic Parkinson's disease
Neurosci Lett
Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease
Neurosci Lett
Lack of association between the interleukin-1 alpha (-889) polymorphism and early-onset Parkinson's disease
Neurosci Lett
A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson's disease for females
Parkinsonism Relat Disord
Microglial response to 6-hydroxydopamine-induced substantia nigra lesions
Brain Res
Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum
Brain Res
Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys
Exp Neurol
Synuclein activates microglia in a model of Parkinson's disease
Neurobiol Aging
The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system
Neurobiol Dis
Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain
Neuroscience
The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse
Exp Neurol
Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism
Prog Neurobiol
Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity
J Biol Chem
Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing
Blood
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Nature
Nondopaminergic neurons in Parkinson's disease
Adv Neurol
Staging of brain pathology related to sporadic Parkinson's disease
Neurobiol Aging
Inflammation and the degenerative diseases of aging
Ann N Y Acad Sci
Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
Neurology
Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease
Mov Disord
The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease
Neuroscience
Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains
Acta Neuropathol
Quantitative study of pathological forms of astroglia in Wilson's disease
Folia Neuropathol
GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons
Science
Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury
Proc Natl Acad Sci USA
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease
J Clin Invest
Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease
Acta Neuropathol
Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease
J Neural Transm Park Dis Dement Sect
Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain
J Neural Transm
FcɛRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells
J Neurosci
Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain
J Neural Transm
Activated microglia mediate neuronal cell injury via a nitric oxide mechanism
J Immunol
Cyclooxygenases 1 and 2
Annu Rev Pharmacol Toxicol
Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice
J Neurosci
Cited by (1548)
CD28<sup>null</sup> T cells in aging and diseases: From biology to assessment and intervention
2024, International ImmunopharmacologyDistinct mechanisms underlying the therapeutic effects of low-molecular-weight heparin and chondroitin sulfate on Parkinson's disease
2024, International Journal of Biological MacromoleculesDepressive Symptoms and the Subsequent Risk of Parkinson's Disease: A Nationwide Cohort Study
2024, American Journal of Geriatric Psychiatry“Lipopolysaccharide-induced animal models for neuroinflammation – An overview.”
2024, Journal of NeuroimmunologyTherapeutic potential of Coumarin-polyphenolic acid hybrids in PD: Inhibition of α-Syn aggregation and disaggregation of preformed fibrils, leading to reduced neuronal inclusion formation
2024, Bioorganic and Medicinal Chemistry Letters